The Treatment of Parkinson's disease: Current concepts and rationale

Comprehensive Therapy

Volumn 24, Issue 11-12, 1998, Pages 560-566

  Hingtgen, Cynthia M ^a,b   Siemers, Eric ^a  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZATROPINE MESILATE; BROMOCRIPTINE MESILATE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE MESILATE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL;

DOSE RESPONSE; DRUG MECHANISM; DYSKINESIA; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEART PALPITATION; HUMAN; LIVEDO RETICULARIS; NERVE DEGENERATION; ORTHOSTATIC HYPERTENSION; PALLIDOTOMY; PARKINSON DISEASE; REVIEW; THALAMOTOMY; URINE RETENTION; VISUAL IMPAIRMENT; XEROSTOMIA;

ANTIPARKINSON AGENTS; CLINICAL TRIALS; FEMALE; GLOBUS PALLIDUS; HUMANS; MALE; PARKINSON DISEASE; PROGNOSIS; THALAMUS; TREATMENT OUTCOME;

EID: 0031735408     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Riederer P, Rausch WD, Schmidt B, et al. Biochemical fundamentals of Parkinson's disease. Mount Sinai J Med. 1988; 55:21-28.
2. Lang A. Manipulating the dopaminergic system in Parkinson's disease. Pharmacol Ther. 1987;32:51-76.
3. Maier Hoehm MM. Parkinson's disease: progression and mortality. Adv Neurol. 1986;45:457-461.
4. Siemers E. Recent progress in the treatment of Parkinson's disease. Compr Ther. 1992;18:20-24.
5. Schwab RS, England AC, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson's disease. JAMA. 1969; 208:1168-1170.
6. Uitti RJ, Rajput AH, Aslskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology. 1996;46:1551-1556.
7. Butzer JF, Silver DE, Sahs AL. Amantadine in Parkinson's disease. Neurology. 1975;25:603-606.
8. Factor SA, Friedman JH. The emerging role of colzapine in the treatment of movement disorders. Mov Disord. 1997;12: 483-496.
9. Wolters Ech, Jansen ENH, Tuynman-Qua HG, Bergmans PLM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 1996; 47:1085-1087.
10. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology. 1990;40:340-345.
11. Fabbrini G, Mouradain MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part 1. Ann Neurol. 1988;24:366-371.
12. Mouradain MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part 2. Ann Neurol. 1988;24:372-378.
13. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled-release carbidopa/levodopa in Parkinson's disease. Eur Neurol. 1997;37:23-27.
14. Fahn S. Is levodopa toxic? Neurology. 1996;47(suppl 3):S184-S195.
15. Goetz CG. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology. 1990;40(suppl 3):50-54.
16. Watts RL. The role of dopamine agonists in early Parkinson's disease. Neurology. 1997;49(suppl 1):S34-S48.
17. Pearce RKB, Banerji T, Jenner P, Marsden CD. Effects of repeated treatment with L-dopa, bromocriptine and ropinirole in drug-naïve MPTP-treated common marmosets. Br J Pharmacol. 1996;118(suppl):37P.
18. Bédard PJ, Di Paolo T, Falardeau P, Boucher R. Chronic treatment with L-dopa, but not bromocriptine, induces dyskinesia in MPTP-parkinsonian monkeys: correlation with [3H]spiperone binding. Brain Res. 1986;379:294-299.
19. Myllylä VV, Sotaniemi K, Mäki-Ikola O, Rinne UK, Heinonen EH. Role of selegiline in combination therapy of Parkinson's disease. Neurology. 1996;47(suppl 3):S200-S209.
20. Olanow CW. Selegiline: current perspectives on issues related to neuroprotection and mortality. Neurology. 1996;47 (suppl 3):S210-216.
21. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321:1364-1371.
22. Kurth MC, Adler CH. COMT inhibition: a new treatment strategy for Parkinson's disease. Neurology. 1998;50 (suppl 5):S3-S14.
23. Goetz CG, Diederich NJ. There is a renaissance of interest in pallidotomy for Parkinson's disease. Nat Med. 1996;2: 510-514.
24. Lang AE, Lozano AM, Montgomery E, Duff J, Tasker R, Hutchinson W. Posteroventral medial pallidotomy in advanced Parkinson's disease. N Engl J Med. 1997;227: 1036-1042.
25. Koller W, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol. 1997;42:292-299.
26. Limousin P, Pollak P, Benazzouz A, et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet. 1995;345:91-95.